Akoya Biosciences (NASDAQ:AKYA) PT Lowered to $14.00 at Piper Sandler

Akoya Biosciences (NASDAQ:AKYA – Get Rating) had its price target decreased by investment analysts at Piper Sandler from $18.00 to $14.00 in a report released on Sunday, The Fly reports. Piper Sandler’s price target indicates a potential upside of 40.99% from the stock’s previous close.

Several other equities research analysts have also commented on AKYA. Zacks Investment Research lowered shares of Akoya Biosciences from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 17th. Morgan Stanley cut their price target on shares of Akoya Biosciences from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 15th.

Akoya Biosciences stock traded up $0.53 during midday trading on Friday, reaching $9.93. The company’s stock had a trading volume of 52,511 shares, compared to its average volume of 67,212. Akoya Biosciences has a fifty-two week low of $8.02 and a fifty-two week high of $23.44. The company has a quick ratio of 4.76, a current ratio of 3.98 and a debt-to-equity ratio of 0.31. The company has a market cap of $373.27 million and a P/E ratio of -6.99. The business has a 50-day simple moving average of $10.70 and a 200-day simple moving average of $11.81.

Akoya Biosciences (NASDAQ:AKYA – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.05). Akoya Biosciences had a negative net margin of 86.00% and a negative return on equity of 39.95%. During the same period last year, the company earned ($2.85) earnings per share. As a group, equities analysts forecast that Akoya Biosciences will post -1.34 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Akoya Biosciences by 12.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 67,401 shares of the company’s stock valued at $741,000 after acquiring an additional 7,243 shares during the period. Parkman Healthcare Partners LLC increased its holdings in shares of Akoya Biosciences by 20.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 150,321 shares of the company’s stock valued at $1,652,000 after acquiring an additional 25,321 shares during the period. Candriam Luxembourg S.C.A. boosted its stake in shares of Akoya Biosciences by 216.7% during the first quarter. Candriam Luxembourg S.C.A. now owns 159,300 shares of the company’s stock worth $1,751,000 after buying an additional 109,000 shares during the period. Vanguard Group Inc. boosted its stake in shares of Akoya Biosciences by 3.8% during the first quarter. Vanguard Group Inc. now owns 700,823 shares of the company’s stock worth $7,702,000 after buying an additional 25,845 shares during the period. Finally, BlackRock Inc. boosted its stake in shares of Akoya Biosciences by 1.4% during the first quarter. BlackRock Inc. now owns 777,001 shares of the company’s stock worth $8,538,000 after buying an additional 10,737 shares during the period. 39.90% of the stock is currently owned by institutional investors and hedge funds.

Akoya Biosciences Company Profile (Get Rating)

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. It offers single-cell resolution with spatial context that provides a wealth of information to visualize tissue organization and disease pathology on a molecular level to understand disease progression and treatment response.

Featured Stories